ARSENAULT KAITLYN 4

What Happened Kaitlyn Arsenault, CFO of Skye Bioscience, received a derivative award on Feb 6, 2026: 125,000 shares listed as a grant/award (transaction code A) at $0.00 (derivative security). This is an equity compensation award (option/rights) rather than an open‑market purchase or sale, so it does not represent an immediate cash investment or disposal.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (filed within the required period).
• Instrument: 125,000-share derivative award (recorded at $0.00 in the filing).
• Vesting: Vests in equal monthly installments over four years beginning January 19, 2026 (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of immediate exercise or sale in this filing.

Context This was a compensation award (typical for executives) that creates a future right to equity as it vests; it is not the same as an immediate purchase (which some investors view as a stronger bullish signal). Because vesting is monthly over four years, any actual acquisition of common shares will occur gradually and only as portions vest and are exercised (if applicable). The filing appears timely, so there is no late‑filing flag.